Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from FDA

The True Story Behind 'Painkiller,' From Richard Sackler to Purdue Pharma

The scripted miniseries covers all angles of the opioid epidemic

Marie Claire

AOC Slams the FDA's Harmful Overregulation of Sunscreen

On this one issue, the democratic socialist sounds a lot like a libertarian.

Reason

Ice cream cups sold in 20 states linked to Listeria outbreak, CDC warns

"Soft Serve On The Go" ice cream cups have been recalled due to potential bacterial contamination.

LiveScience

From analysis to the latest developments in health,
read the most diverse news in one place.

Premium Cigars Escape FDA Regulation for Now

The FDA failed to consider whether premium cigars warranted a different regulatory approach than cigarettes.

Reason

A pharma company helping Elon Musk shed weight is now worth more than the entire economy of Denmark

The weight-loss and diabetes injectables have seen a surge in demand primarily in the U.S., buoying Novo Nordisk’s profits in the first half of 2023.

Fortune

Coronavirus FAQ: Is it wiser to get a booster now or wait for the new fall booster?

Maybe it's not a full-blown summer surge but COVID numbers are ticking up. For those with concerns due to personal risk factors or the start of the school year, the booster question is top of mind.

WEKU

Insurers won't cover new Alzheimer's treatment for some customers

Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer’s patients

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Suicide Down 8.4 Percent Among Teens and Young Adults

Plus: How would Jesus vote?, appeals court strikes gun ban for marijuana users, and more...

Reason

Can Ozempic and Wegovy cause 'stomach paralysis' and 'cyclic vomiting'?

"Stomach paralysis" linked to drugs like Ozempic has raised alarm. What do doctors make of the reports?

LiveScience

Elon Musk-Backed Brain Chip Company Neuralink Gets $280 Million In Funding

Neuralink receives approval from the FDA for human experiment trials as experimentation looms.

Zenger

Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?

Eli Lilly stock has sold off alongside the broader market over the last week, undercutting its moving averages. Is LLY stock a sell?

Investors Business Daily

What we know — and don't know — about the FDA-approved postpartum depression pill

Postpartum depression affects as many as 1 in 7 women in the U.S., though there are just two treatments approved for it. Experts say the newest could be a game-changer — depending on its price tag.

WEKU

3 Pharma Stocks Investors Are Chasing for Value

With the advent of advanced medications and the increasing need for personalized treatments, the pharmaceutical industry looks well-poised for long-term growth. Therefore, it could be worth looking into three fundamentally sound pharma stocks, Pfizer (PFE), Sanofi (SNY), and GSK plc (GSK), that are offering significant value. Read more….

StockNews.com

More gay men can donate blood—here's why

A policy that wasn't rooted solely in science is diminished, but certain barriers to blood donation still remain

Salon

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin

Astellas Pharma won FDA approval for a rival to Apellis Pharmaceuticals' eye-disease treatment and APLS stock plunged Monday.

Investors Business Daily

Why Sage Lost Half Its Value After The FDA Approved Its Depression Drug

Sage stock plummeted Monday after the FDA approved its drug, Zurzuvae, in postpartum depression, but not major depressive disorder.

WEKU

Up First briefing: Trump fights protective order; FDA approves postpartum pill

Donald Trump's legal team has until 5:00 p.m. to respond to prosecutors' request for a protective order. The FDA has approved the first pill to treat postpartum depression.

WEKU

Ozempic and Wegovy maker courts prominent Black leaders to get Medicare's favor

Drugmaker Novo Nordisk focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease — worth treating at a cost of $1,000 or more a month.

Get all your
news in one place.

100’s of premium titles.
One news app.

Salon

FDA approves postpartum depression pill

Here’s what we know about the second drug to ever be approved for the post-pregnancy condition

WEKU

RSV prevention shot for babies gets OK from CDC

The monoclonal antibody drug prevents the lung infection that puts 58,000 to 80,000 young children in the hospital each year.

WEKU

The FDA approves the first pill specifically intended to treat postpartum depression

The Food and Drug Administration granted approval of the drug, Zurzuvae, for adults experiencing severe depression related to childbirth or pregnancy. The pill is taken once a day for 14 days.

The Independent UK

FDA approves first postpartum depression pill

Federal health officials have approved the first pill to specifically treat depression after childbirth

Zenger

Nikola’s Abrupt CEO Transition, Carl Icahn Led Icahn Enterprises Cuts Dividend Payout, FDA Rejects Mesoblast’s Cell Therapy For Kids: Today’s Top Stories

Wall Street Journal UAW Demands Significant Wage Increases For Factory Workers At GM, Ford, And Stellantis

LiveScience

'Powerful' new RSV prevention drug should be available to all infants this fall, CDC says

Come fall, a new antibody drug should be available to protect U.S. newborns and infants younger than 8 months from severe RSV infections.

StockNews.com

3 Biotech Stocks Smart Money Is After

Biotech companies such as Biogen (BIIB), Cidara Therapeutics (CDTX), and Theratechnologies (THTX) with the interest of institutional investors could be worth investing in now. Continue reading….

1 … 75 76 77 78

People

Alexandria OcasioCortez

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.